What Solifenacin Teva treats: main uses and benefits

Solifenacin Teva belongs to a group of medicines called anticholinergics. These medications are used to reduce the activity of an overactive bladder, allowing the patient to wait longer before needing to go to the toilet and increasing the amount of urine that the bladder can hold.

Main Uses

Solifenacin Teva is used for the treatment of the symptoms of a condition called overactive bladder. These symptoms include:

• Urgency: Having a strong, sudden urge to urinate without prior warning.
• Frequency: Needing to urinate more often than usual.
• Urge Incontinence: Involuntary leakage of urine because the patient was unable to get to the toilet in time.

Benefits and Mechanism of Action

The active substance in Solifenacin Teva works by reducing the activity of the bladder muscle. It helps the bladder to relax, which assists in managing the symptoms associated with an overactive bladder. By decreasing the frequency of involuntary bladder contractions, the medication helps to:

• Increase the volume of urine the bladder can contain.
• Decrease the frequency of urination.
• Reduce the number of urgent episodes or accidents associated with the condition.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility and Contraindications

Solifenacin Teva is contraindicated in patients with specific severe conditions, meaning use is strictly prohibited. These conditions include urinary retention (inability to empty the bladder), gastric retention, uncontrolled narrow-angle glaucoma, Myasthenia Gravis, or a known hypersensitivity to solifenacin succinate or its ingredients. Use is also contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) or those undergoing hemodialysis.

Age-Group Eligibility
Adults (18+): Eligible for tablet use under standard labeled conditions.
Children (2+ years): Eligible for the oral suspension form for Neurogenic Detrusor Overactivity; tablets are not established for safety or efficacy in children under 18.
Geriatric Patients: Use is established, with no substantial differences in safety or effectiveness compared to younger adults.

Eligibility is restricted for patients with severe renal impairment or moderate hepatic impairment (Child-Pugh B). For these populations, the regulatory label mandates that the maximum dose must not exceed 5 mg once daily. Use is further restricted when potent CYP3A4 inhibitors are co-administered.

Use during pregnancy requires caution, as the potential risk to humans is unknown (US labeling is Pregnancy Category C). Use during breastfeeding should be avoided, as the drug passes into milk in animal studies and effects on the infant are unknown.

Interactions with other medicines and products

Solifenacin Teva's interaction profile is primarily defined by its metabolism and its pharmacological class as an antimuscarinic agent, based on official regulatory documentation.

---

Pharmacokinetic and Metabolic Interactions

Solifenacin is a substrate primarily metabolized by the enzyme CYP3A4. Co-administration with potent CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) significantly increases the plasma exposure (AUC and Cmax) of solifenacin.

• Contraindicated Combination: This combination with a potent CYP3A4 inhibitor is formally prohibited in patients with pre-existing severe renal impairment or moderate hepatic impairment (Child-Pugh B).
• Food Interaction: Regulatory studies confirm that co-administration with food does not significantly affect the pharmacokinetics of solifenacin.

---

Pharmacodynamic Interactions and Restrictions

Interactions may occur when combining Solifenacin Teva with other agents that share similar or opposing pharmacological activity:

• Other Anticholinergic Agents: Co-administration may result in additive effects, requiring caution due to potentially more pronounced effects.
• Cholinergic Agonists: The effect of Solifenacin Teva may be reduced when co-administered with cholinergic receptor agonists.
• Gastrointestinal Motility Stimulants: Solifenacin Teva may reduce the effect of medicines intended to stimulate intestinal movement (e.g., Metoclopramide).
• Timing Restriction: Following the discontinuation of Solifenacin Teva, an interval of approximately one week should be allowed before commencing other anticholinergic therapy.

How Solifenacin Teva Works

Solifenacin Teva acts by targeting the nerve signaling pathway that mediates the function of the bladder wall. Its mechanism involves interrupting the chemical messages responsible for initiating involuntary muscle contraction.

---

Competitive Blockade of M3 Receptors

The primary mechanism involves competitive antagonism at the Muscarinic Acetylcholine Receptor (M3 subtype), which is highly expressed on the surface of the detrusor smooth muscle cells. The drug acts by physically occupying the receptor site, preventing the natural neurotransmitter, acetylcholine (ACh), from binding and initiating the contraction signal. The binding action prevents signaling along the cholinergic pathway responsible for detrusor muscle excitability.

---

Modulation of Detrusor Smooth Muscle Tone

The consequence of blocking the M3 receptors is a reduction in the cellular signaling that triggers muscle shortening. This modulation leads to relaxation of the detrusor muscle and a decrease in its intrinsic tension, primarily within the peripheral nervous system context of the lower urinary tract. The physiological changes result in an increased vesical capacity due to enhanced compliance and volume accommodation by the organ.

How to Use Solifenacin Teva

The administration of Solifenacin Teva (solifenacin succinate) follows a standardized protocol to ensure consistent and proper use. The medicine is exclusively for oral administration and is available as 5 mg and 10 mg tablets, or as a 1 mg/mL oral suspension.

---

Standard Dosing and Frequency

Solifenacin is administered once daily for all approved uses. For adults, the typical starting dose is 5 mg once daily, which may be increased to a maximum of 10 mg once daily if the initial dose is well tolerated. The tablets must be swallowed whole with liquid and should not be crushed, broken, or chewed. Administration is permissible with or without food.

---

Population-Specific Administration

Patient Group	Dosing Requirement
Pediatric Patients (2 years)	Dosing is weight-based using the oral suspension only.
Severe Renal/Moderate Hepatic Impairment	The daily dose must not exceed 5 mg.
Co-administration with CYP3A4 Inhibitors	The maximum daily dose must be restricted to 5 mg.

---

Procedural Guidance

This medication is typically intended for long-term treatment. If a dose is missed, the instruction is to take the dose as soon as it is remembered on the same day. Patients are explicitly directed not to take two doses in one day to make up for a missed dose.

Solifenacin Teva: Recent Clinical Evidence

Clinical research on solifenacin focuses primarily on its use in managing the symptoms of Overactive Bladder (OAB). The drug is classified as an antimuscarinic agent, with studies exploring its action as a selective antagonist of the M3 muscarinic receptor. This activity is associated with a reduction in involuntary bladder muscle contractions.

Efficacy and Symptom Reduction

Multiple randomized, placebo-controlled trials have examined the effect of solifenacin in adults with OAB symptoms, including urinary urgency, frequency, and urge incontinence. Pooled data from large analyses suggest that, compared to placebo, treatment with solifenacin is associated with a greater change in key diary variables:

Diary Variable	Research Finding (vs. Placebo)
Micturition Frequency	Significant reduction in episodes per 24 hours
Urgency Episodes	Significant reduction in episodes per 24 hours
Incontinence Episodes	Significant reduction in episodes per 24 hours
Volume Voided	Significant increase in the volume voided per micturition

Some trials have also investigated the effect of solifenacin in combination with other classes of OAB medication, such as beta-3 adrenergic receptor agonists, with these combination regimens being evaluated for potential further changes in symptoms and quality of life metrics.

Tolerability Profile

Solifenacin's safety profile has been documented across numerous studies. The most frequently reported adverse events are typically related to its anticholinergic properties. Commonly observed events include dry mouth, constipation, and blurred vision, which were generally reported as mild to moderate in intensity and were observed more frequently in the treatment group compared to the placebo group. Research has also explored the safety and efficacy of solifenacin in specific groups, including pediatric patients with neurogenic detrusor overactivity.

Key Studies & References

1. Combination therapy with solifenacin and a beta-3 adrenergic receptor agonist for overactive bladder: A systematic review and meta-analysis

Common questions about Solifenacin Teva (FAQ)

Q: What is Solifenacin Teva actually used to treat?

According to official regulatory documents, Solifenacin Teva (solifenacin succinate) is approved to treat symptoms associated with Overactive Bladder (OAB). This includes helping with issues like urinary urgency, frequency, and urge incontinence. It is also approved for treating Neurogenic Detrusor Overactivity (NDO), a bladder control issue, in eligible pediatric patients.

Q: Is Solifenacin Teva the same as Vesicare?

Solifenacin Teva is described as a generic version of the medicine originally sold under the brand name Vesicare. Both contain the same active ingredient, solifenacin succinate. Generic and brand-name versions are generally expected to be therapeutically equivalent by government regulatory authorities.

Q: How quickly should Solifenacin Teva start to work?

Official information indicates that the active substance reaches its highest level in the bloodstream within 3 to 8 hours of taking a dose. However, the full therapeutic benefit—the noticeable improvement in bladder symptoms—may take longer, and in clinical studies, the full therapeutic effect has been observed after 4 to 6 weeks of use.

Q: How long does the effect of one dose of Solifenacin Teva last?

Solifenacin Teva is designed for once-daily dosing, meaning one dose is intended to provide effects over 24 hours. Studies show that the half-life, which is the time it takes for half of the medicine to be eliminated from the body after long-term use, is approximately 45 to 68 hours. This supports its long duration of action.

Q: What should I know about taking Solifenacin Teva with alcohol?

Regulatory documents do not explicitly prohibit alcohol use with this medicine. However, the official product information notes that Solifenacin Teva can cause central nervous system (CNS) side effects like dizziness and somnolence (drowsiness). Using alcohol while taking this medicine may increase the likelihood or severity of these effects.

Q: Is it common for people to stop taking Solifenacin Teva due to side effects?

Clinical trial data included in regulatory submissions show that the rate of people discontinuing treatment specifically due to side effects is relatively low. For instance, some long-term studies report this rate to be approximately 5% of patients.

Q: Can Solifenacin Teva interact with over-the-counter pain relievers?

According to drug interaction databases and official patient information, common non-prescription pain relievers like paracetamol and ibuprofen are generally compatible with Solifenacin Teva. Nevertheless, it is important that patients inform a healthcare professional about all concurrent medicines.

Q: What is the main difference between Solifenacin and other bladder medicines?

Solifenacin belongs to the antimuscarinic class of medicines, meaning it primarily works by relaxing the bladder muscle. It is typically a once-daily medicine. Compared to some older medicines in the same class, studies reviewed by regulators often suggest that Solifenacin has been associated with a more favorable balance of effectiveness and tolerability, particularly concerning common side effects like dry mouth.

Q: Does Solifenacin Teva affect blood pressure?

Solifenacin is not primarily a blood pressure medicine. However, official labeling highlights that it can increase the risk of QT prolongation, which is an effect on the electrical system of the heart. Official labeling highlights that use is restricted for patients at high risk of QT prolongation or those using other medicines that can cause a similar effect.

Q: Can Solifenacin Teva be taken by people with heart conditions?

Official information indicates that regulatory documents restrict use for patients considered to be at high risk of QT prolongation. This high-risk group includes individuals with certain known heart conditions or those who are taking other medicines known to affect the heart's electrical rhythm.

Q: Is Solifenacin Teva suitable for both men and women?

Yes, official clinical studies used to evaluate the effectiveness of solifenacin included both men and women. The evidence indicated that the medicine's effectiveness was found to be similar across adult patient age and gender.

Q: Is Solifenacin Teva known to interact with herbal supplements?

While specific interaction studies are often not available for all herbal supplements, caution is advised. Any herbal supplement that causes side effects similar to Solifenacin Teva, such as drowsiness or difficulty passing urine, may potentially worsen these effects due to additive action. Patients are advised to inform a healthcare professional of all supplements being taken.

Q: Is there a risk of developing tolerance to Solifenacin Teva over time?

Long-term studies reviewed by regulatory bodies, spanning periods of up to 12 months, examined the effect of this medicine over time. The results showed that its therapeutic effect was maintained over the treatment period examined.

Q: Is it safe to drive while taking Solifenacin Teva?

Regulatory documents advise that this medicine may cause side effects such as somnolence (drowsiness), dizziness, and blurred vision. Patients should exercise caution regarding driving or operating machinery until they are aware of their personal response to the medicine.

Q: Can Solifenacin Teva interact with antibiotics?

Yes, interaction is possible because Solifenacin Teva is metabolized primarily by the CYP3A4 enzyme system. Certain macrolide antibiotics, such as erythromycin, are known to block this enzyme. If these are used concurrently with Solifenacin, regulatory guidance indicates that the maximum daily dose of Solifenacin may be restricted.

Q: Are there any known withdrawal symptoms if Solifenacin Teva is stopped suddenly?

Regulatory documents do not list a specific formal withdrawal syndrome. If the medicine is discontinued, the original symptoms the drug was treating, such as urinary urgency and frequency, are expected to return as the medicine's effect fades.

Q: Do regulatory documents mention any black box warnings for Solifenacin Teva?

The official FDA labeling for Solifenacin succinate does not include a Boxed Warning (also known as a Black Box Warning).

Q: Does Solifenacin Teva cause any emotional or mood changes?

Regulatory documents list central nervous system effects that have been reported in post-marketing experience. These include reports of confusion, hallucinations, and, rarely, delirium. Patients should inform a healthcare professional of any changes in mood or mental status observed.

Q: Why do some people experience dry eyes with Solifenacin Teva?

Solifenacin is classified as an antimuscarinic agent, meaning it works by temporarily blocking certain receptors across the body. This blocking action can extend to the receptors that regulate functions in the eye, which may result in anticholinergic side effects such as blurred vision and dry eyes.

Q: Does Solifenacin Teva interact with common antidepressants or anxiety medicines?

Interaction is possible because many antidepressants (such as tricyclics) and anxiety medicines have either anticholinergic effects or involve the CYP3A4 enzyme system. Combining agents with similar actions may lead to additive side effects, and concurrent use may need to be assessed by a health professional.

Q: Can I take Solifenacin Teva if I am taking medicines for acid reflux?

Solifenacin Teva is known to reduce the effectiveness of medicines that are intended to stimulate movement in the gut. While most standard acid reflux medicines may not typically fall into this category, use with patients experiencing slow or decreased gastrointestinal motility may require caution, as it may affect their existing condition.

Q: Is there any information about Solifenacin Teva and weight changes?

Based on clinical studies and official post-marketing reports, Solifenacin Teva is not generally expected to cause changes in body weight. However, rare post-marketing reports have included the side effect of decreased appetite (anorexia).

Q: Why is Solifenacin Teva often prescribed instead of oxybutynin?

Both medicines are used for overactive bladder. Regulatory-supported comparisons often highlight that Solifenacin Teva has been associated with a lower incidence of certain common side effects, such as dry mouth and some cognitive effects, compared to older antimuscarinics like oxybutynin. This difference in side effect profile is a factor discussed in the context of patient adherence to treatment.

Q: How is Solifenacin Teva eliminated from the body?

According to official pharmacokinetic data, the active substance and its metabolites are eliminated from the body primarily through the body’s excretory systems. Approximately 69% is excreted via the urine and about 23% via the feces.

Q: Is it safe to take Solifenacin Teva with daily vitamins or supplements?

General vitamins are not typically expected to cause interactions. However, any supplement that affects the CYP3A4 enzyme system or causes anticholinergic effects (like dry mouth or drowsiness) should be used cautiously. Official guidance notes the importance of informing a healthcare professional of all supplements.

Official Storage and Disposal Requirements

The storage and disposal instructions for Solifenacin Teva are defined by regulatory labeling to maintain product stability and ensure safety.

Storage Conditions

Formulation	Temperature Requirement	Stability/Container Rule
Tablets	Store at Controlled Room Temperature (20 C to 25 C)	Store in the original package to protect from moisture.
Oral Suspension	Store at Room Temperature; Do not freeze.	Keep bottle tightly closed; Discard 28 days after first opening.

Child Safety and Disposal

All forms of the medication must be kept out of the sight and reach of children.

Unused or expired Solifenacin Teva must not be disposed of via wastewater or regular household waste and should be discarded safely according to local regulatory requirements.